Reshape Lifesciences (RSLS) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Reshape Lifesciences in July 2026.
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying ReShape Lifesciences' stock, with a significant target price of $58.
Financial Health
ReShape Lifesciences is performing well with strong revenue and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RSLS
Obesity Drug Distribution via Telehealth Platforms Explained
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Published: 1 April 2026
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketOzempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: 15 August 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: 13 August 2025
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.